Premium
Potential antitumor applications of a monoclonal antibody specifically targeting human papilloma virus 16 E7 49–57 peptide
Author(s) -
Lei Jianqiang,
Zhang GaoXia
Publication year - 2012
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2012.00456.x
Subject(s) - epitope , monoclonal antibody , isotype , biology , peptide , antibody , microbiology and biotechnology , mhc class i , cancer research , potency , major histocompatibility complex , immunotherapy , virology , antigen , cancer , computational biology , immunology , biochemistry , genetics , in vitro
Our study aims to evaluate whether the approach of TCRm mAb has therapeutic potential against HPV‐induced tumors. In the present study, we generated a murine IgG2a mAb 6C10 specifically recognizing HPV‐16‐E7 49–57 epitope (RAHYNIVTF) in the polypeptides and in complex with a MHC class I molecule. Analysis of the primary structure shows that the 6C10 Ab displays a novel sequence in the CDR of the heavy chain, compared to the sequences in the Kabat database, which suggests the Ab has completed its affinity maturation. The 6C10 Ab can specifically recognize E7 and Trx‐E7 30–67 protein in ELISA, and can also specifically bind to T2 cell carrying HPV‐16‐E7 49–57 peptide. In the TC‐1 cell tumor‐bearing mouse model, 6C10 exhibits tumor suppression activity when compared to the isotype control Ab. 6C10 Ab has showed tumor‐inhibition potency in a mouse model and this Ab may have the prospect of cancer therapy.